Doxorubicin, Paclitaxel and Gemcitabine: A Phase I Study of a New Sequential Treatment in Stage III B - IV Breast Cancer

T. Ibrahim, M. Fabbri, G. L. Frassineti, W. Zoli, M. Monti, L. Ricotti, D. Amadori

Research output: Contribution to journalArticle

Abstract

Based on the synergistic interactions of the sequence doxorubicin- paclitaxel-gemcitabine obtained in our preclinical study, a Phase I trial was conducted to evaluate the feasibility of this new sequence in breast cancer. Patients with stage IIIB-IV breast cancer received doxorubicin on day 1, paclitaxel on day 2 and gemcitabine on day 6 and 13 (steps IIa, III and V) in cohorts of 3 patients. From March 1999 to December 2000, 9 patients were treated. The most important toxicity was hematological. The maximum tolerated dose was reached at the second level because dose-limiting toxicity occurred in 3 patients. Non hematological toxicities were alopecia, diarrhea, asthenia, nausea, mucositis, paresthesia and myalgia. A Phase II trial is ongoing to further investigate the activity of this new sequential treatment with doxorubicin (50 mg/m 2 day 1), paclitaxel (160 mg/m 2 day 2) and gemcitabine (800 mg/m 2 day 6) in advanced breast cancer.

Original languageEnglish
Pages (from-to)488-494
Number of pages7
JournalJournal of Chemotherapy
Volume15
Issue number5
Publication statusPublished - Oct 2003

Keywords

  • Breast cancer
  • Doxorubicin
  • Gemcitabine
  • Paclitaxel
  • Phase I trial

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Doxorubicin, Paclitaxel and Gemcitabine: A Phase I Study of a New Sequential Treatment in Stage III B - IV Breast Cancer'. Together they form a unique fingerprint.

  • Cite this